A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Cancer

Volumn 120, Issue 11, 2014, Pages 1647-1655

  Garcia, Jorge A ^a   Hudes, Gary R ^b   Choueiri, Toni K ^c   Stadler, Walter M ^d   Wood, Laura S ^a   Gurtler, Jayne ^e   Bhatia, Shailender ^f,g   Joshi, Adarsh ^h   Hozak, Rebecca R ^h   Xu, Yihuan ⁱ   Schwartz, Jonathan D ⁱ   Thompson, John A ^f,g  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Metarie Oncology   (United States)

^f SEATTLE CANCER CARE ALLIANCE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ ImClone Systems Inc   (United States)

Author keywords

metastatic; monoclonal antibody; phase 2; ramucirumab; renal cell carcinoma

Indexed keywords

RAMUCIRUMAB; SORAFENIB; SUNITINIB;

ADULT; AGED; ANOREXIA; ARTERIAL THROMBOEMBOLISM; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; KIDNEY FAILURE; KIDNEY METASTASIS; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

METASTATIC; MONOCLONAL ANTIBODY; PHASE 2; RAMUCIRUMAB; RENAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84901301933     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28634     Document Type: Conference Paper

References (28)

1. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14: 4726-4734.
2. Flaherty KT, Puzanov I,. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol. 2010; 80: 638-646.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
6. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-1939.
7. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
8. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
9. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28: 780-787.
10. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z,. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 2002; 97: 393-399.
11. Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003; 278: 43496-43507.
12. Chiorean E, Sweeney C, Hurwitz H, et al. Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 monoclonal antibody (MoAb) IMC-1121B, administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers [abstract B15]. Paper presented at: 19th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; October 22-26, 2007; San Francisco, California.
13. Surguladze D, Plym MJ, Prewett M, Schwartz JD, Pytowski B. Efficacy of VEGFR2 targeted monoclonal antibody therapy in preclinical models of hepatocellular carcinoma [abstract]. Proc ILCA. 2013; 6: 39. Abstract P-043.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
15. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999; 59: 5209-5218.
16. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. Available at: http://ctep.cancer.gov/. Accessed April 19, 2013.
17. Miller RG, Siegmund D,. Maximally selected chi square statistics. Biometrics. 1982; 38: 1011-1016.
18. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454-463.
19. Heng DY, Xie W, Bjarnason GA, et al. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study [abstract]. J Clin Oncol. 2010; 28 (suppl 15). Abstract 4523.
20. Fuchs CS, Tomasaek J, Cho JY, et al. REGARD: a phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy [abstract]. J Clin Oncol. 2012; 30 (suppl 34). Abstract LBA5.
21. Di LG, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009; 27: 4469-4474.
22. Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010; 116: 5383-5390.
23. Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial [abstract LBA22]. Paper presented at: 37th Congress of the European Society for Medical Oncology (ESMO); September 28 to October 2, 2012; Vienna, Austria.
24. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23: 3697-3705.
25. Shah MA, Ilson D, Kelsen DP,. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005; 23: 2574-2576.
26. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-2143.
27. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103: 763-773.
28. Choueiri TK, Pal SK, McDermott DF, et al. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2012; 30 (suppl 5). Abstract 364.